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Abstract
Background: Dexamethasone is widely used in cancer patients despite the concern that perioperative glucocorticoids
may potentially cause immunosuppression. However, studies on the influence of dexamethasone on cancer recurrence
after curative surgery have produced conflicting results. The goal of our study was to compare postoperative recurrence-
free survival and overall survival between patients with breast cancer who received perioperative dexamethasone and
those who did not.
Methods: The medical records of 2729 patients who underwent breast cancer surgery between November 2005 and
December 2010 were reviewed. These patients were followed up until December 2015. The patients were categorised
according whether they received a single dose of intravenous dexamethasone perioperatively or not. Cox regression
analyses were conducted to evaluate any associations between dexamethasone usage with postoperative recurrence
and mortality. Additionally, we performed a sensitivity test with propensity score matching to adjust for selection bias.
Results: Among the 2628 patients, 236 (8.5%) received perioperative dexamethasone. No increasing risk for recurrence
(hazard ratio [HR], 1.442; 95% confidence interval [CI], 0.969–2.145; P = 0.071) or mortality (HR, 1.256; 95% CI, 0.770–2.047;
P = 0.361) after breast cancer surgery were identified in patients who received dexamethasone. Similarly, propensity score
matching did not show significant associations in postoperative recurrence (HR, 1.389; 95% CI, 0.904–2.132; P = 0.133) or
mortality (HR, 1.506; 95% CI, 0.886–2.561; P = 0.130) in patients who received dexamethasone.
Conclusions: We found that a perioperative single dose of dexamethasone is not associated with increased recurrence
or mortality after curative surgery in breast cancer patients.
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Background
Even though surgery is the best curative option for solid
tumours, surgical manipulation still carries a risk of
tumour spreading. Even after complete removal, tumour
cells released during surgery may eventually lead to
recurrence if they escape immune surveillance [1–3]. It
is well known that corticosteroids induce generalized
immunosuppression [4], and dexamethasone in particu-
lar can significantly suppress lymphokine production
and cell proliferation [4], impair natural killer function
[5, 6], and promote resistance to apoptosis in tumour
cells [7].
However, many anaesthesiologists prefer to administer
a single dose of dexamethasone because perioperative
administration of this corticosteroid (4–10mg intraven-
ously) can reduce postoperative nausea/vomiting and
surgical pain, and it can also enhance the quality of life
during recovery, including the patient’s emotional state
and physical independence [8, 9]. Despite its widespread
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Table 1 Comparison of characteristics between patients who received dexamethasone and those who did not
Non-dexamethasone
(N = 2392)
Dexamethasone
(N = 236)
P-value
Demographic data
Age (years) 50.1 ± 10.3 49.5 ± 9.3 0.418
BMI (kg m−2) 23.3 ± 3.1 23.4 ± 3.1 0.764
Comorbidity
HTN 473 (19.8) 44 (18.6) 0.732
DM 172 (7.2) 14 (5.9) 0.594
Cardiac disease 60 (2.5) 4 (1.7) 0.656
Pulmonary disease 46 (1.9) 6 (2.5) 0.463
Endocrine disease 109 (4.6) 14 (5.9) 0.332
Renal disease 16 (0.7) 1 (0.4) > 0.999
Liver disease 16 (0.7) 2 (0.8) 0.673
Neurological disease 40 (1.7) 4 (1.7) > 0.999
Others 14 (0.6) 3 (1.3) 0.191
Anaesthetic factors
Anaesthetic agent 0.001
Volatiles
Sevoflurane 1461 (61.1) 141 (59.7)
Desflurane 613 (25.6) 47 (19.9)
Isoflurane 242 (10.1) 27 (11.4)
Enflurane 31 (1.3) 10 (4.2)
TIVA 45 (1.9) 11 (4.7)
Induction agents 0.029
Propofol 1856 (77.6) 168 (71.2)
Barbiturate 536 (22.4) 68 (28.8)
N2O 176 (7.4) 28 (11.9) 0.021
Premedicationa 1585 (66.3) 169 (71.6) 0.111
Antiemetic 2069 (86.5) 180 (76.3) < 0.001
Rescue analgesics 2297 (96.0) 225 (95.3) 0.602
Hypertensive events 145 (6.1) 15 (6.4) 0.886
Hypotensive events 343 (14.3) 25 (10.6) 0.140
Colloid administration 36 (1.5) 6 (2.5) 0.267
RBC transfusion 12 (0.5) 0 (0) 0.616
Surgical factors
Surgical procedure 0.014
BCS 1156 (48.3) 94 (39.8)
Mastectomy 1218 (51.7) 170 (60.2)
Surgical duration (min) 207.2 ± 131.0 212.5 ± 108.5 0.487
TNM staging 0.974
1 1126 (47.1) 113 (47.9)
2 876 (36.7) 86 (36.4)
3 387 (16.2) 37 (15.7)
Receptors
Oestrogen 1652 (69.1) 173 (73.3) 0.183
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use, there have been few clinical studies evaluating the
influence of perioperative dexamethasone on oncological
outcomes with conflicting results.
Breast cancer is one of the most common malignancies
in women and is a leading cause of death globally.
Although many studies on the treatment of breast cancer
and prevention of postoperative recurrence have been per-
formed, the 10-year survival rate in Western Europe is still
70% [10]. Therefore, it is necessary to investigate how
dexamethasone, frequently used in the perioperative
period, affects the outcomes of breast cancer, to address
concerns about its immunosuppressive properties.
Methods
Subjects
Our protocol was approved by the Institutional Review
Board and Hospital Research Ethics Committee of
Severance Hospital, Yonsei University Health System
(4-2017-0677). The board waived the requirement for in-
formed consents because this study was retrospective.
The data were collected from the electronic medical
documents of patients who underwent curative surgery
of breast cancer at a tertiary single institution between
November 2005 and December 2010. All data were ana-
lysed except those of patients who underwent multiple
surgeries simultaneously, lacked anaesthesia or surgical
information, or received steroid therapy for any reason.
Data collection
Retrieved demographic data of the patients included age,
sex, body mass index (BMI), co-morbidities, induction
agents, anaesthetic agents, and antiemetic agents and
analgesics. Dexamethasone was administered periopera-
tively at the discretion of the anaesthesiologists. We also
collected surgical information including the surgical pro-
cedure and duration, expressed cellular receptors,
tumour-node-metastasis (TNM) staging, tumour type,
histological type, and any administered chemotherapy or
radiotherapy. Clinicopathological parameters, including
levels of oestrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor
(HER) 2, were obtained from the registry database.
Tumours with ≥1% of their cells exhibiting ER and/or
PR staining were considered positive for these receptors.
In addition, we used the American Joint Committee on
Cancer 7th edition criteria to identify the TNM staging
[11]. Local (or regional) metastasis was determined as
tumour recurrence in the ipsilateral breast, regional
lymph nodes, and/or chest wall. Every 6–12 months, the
patients were observed clinically, which included taking
a medical history, performing a physical examination,
and performing laboratory and imaging tests to detect
any cancer relapse. Any recurrence at a distant site, in-
cluding the contralateral axillary or supraclavicular
lymph nodes, was defined as a distant metastasis.
Recurrence-free survival was calculated from the date of
surgery to the date on which loco-regional or distant
metastasis was first detected. The postoperative overall
survival was assessed from the first date of curative sur-
gery to the last follow-up date or death from any cause.
Statistical analyses
Patients who received dexamethasone and those who did
not were compared using Student’s t-test for continuous
Table 1 Comparison of characteristics between patients who received dexamethasone and those who did not (Continued)
Non-dexamethasone
(N = 2392)
Dexamethasone
(N = 236)
P-value
Progesterone 1506 (63.0) 151 (64.0) 0.778
HER2 658 (27.5) 60 (25.4) 0.540
Histological analysis 0.118
Well-differentiated 508 (21.2) 48 (20.3)
Moderately differentiated 1058 (44.2) 105 (44.5)
Poorly differentiated 584 (24.4) 48 (20.3)
Others 242 (10.1) 35 (14.8)
Tumour types 0.818
IDC 2105 (88.0) 212 (87.7)
ILC 85 (3.6) 10 (4.2)
Others 202 (8.4) 19 (8.1)
Chemotherapy 1619 (67.7) 179 (75.8) 0.010
Radiotherapy 1559 (65.2) 137 (58.1) 0.032
Data are presented as mean ± standard deviation, or number (percentage)
BMI body mass index, HTN hypertension, DM diabetes mellitus, TIVA total intravenous anaesthesia, N2O nitrous oxide, RBC red blood cell, BCS breast conserving
surgery, TNM tumour–node–metastasis, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma
aPremedication: Midazolam 0.03 mg kg−1 was administered
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Table 2 Competing risk analyses of factors associated with cancer recurrence after surgery for breast cancer
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Dexamethasone
No 1 (ref) 1 (ref)
Yes 1.348 0.912 1.994 0.134 1.442 0.969 2.145 0.071
Age 0.989 0.976 1.002 0.089
Age (years)
< 40 1 (ref) 1 (ref)
40–49 0.673 0.469 0.967 0.032 0.866 0.598 1.254 0.447
50–59 0.705 0.482 1.032 0.072 0.779 0.526 1.154 0.213
60–69 0.665 0.421 1.05 0.080 0.703 0.416 1.188 0.188
≥70 0.563 0.254 1.249 0.158 0.591 0.247 1.414 0.237
BMI 0.99 0.948 1.034 0.654
BMI (kg m−2)
< 18.4 1.033 0.523 2.039 0.927 0.835 0.421 1.658 0.607
18.4–22.9 1 (ref) 1 (ref)
23–24.9 1.026 0.739 1.423 0.880 1.100 0.791 1.530 0.572
25–29.9 1.033 0.749 1.426 0.842 1.021 0.738 1.411 0.901
≥30 0.73 0.298 1.789 0.491 0.626 0.254 1.546 0.310
HTN
No 1 (ref) 1 (ref)
Yes 0.952 0.686 1.322 0.770 1.045 0.714 1.531 0.820
DM
No 1 (ref) 1 (ref)
Yes 1.132 0.700 1.832 0.612 1.158 0.681 1.968 0.588
Anaesthetic agents
TIVA 1 (ref) 1 (ref)
Volatile 1.247 0.550 2.830 0.597 1.072 0.470 2.441 0.869
N2O
No 1 (ref)
Yes 1.325 0.879 1.997 0.179
Transfusion
No 1 (ref)
Yes 2.591 0.644 10.426 0.180
Premedicationa
No 1 (ref)
Yes 0.878 0.670 1.150 0.345
Surgical procedure
BCS 1 (ref) 1 (ref)
Mastectomy 2.516 1.883 3.360 < 0.001 1.934 1.429 2.618 < 0.001
TNM staging
1 1 (ref) 1 (ref)
2 2.397 1.674 3.431 < 0.001 1.778 1.168 2.706 0.007
3 7.395 5.217 10.48 < 0.001 5.300 3.433 8.183 < 0.001
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variables and the X2 test for categorical variables. P-values
less than 0.05 were considered statistically significant. All
potential confounders associated with recurrence and
mortality after breast cancer surgery, which were chosen
based on their clinical significance as reported in the lit-
erature were analysed using competing risk and Cox re-
gression analyses, respectively. First, we performed
univariate analysis to identify potential risk factors for
postoperative recurrence and mortality; those with
P-values of < 0.1 were subjected to multivariate analysis,
following which hazard ratios (HRs) and the associated
95% confidence intervals (CIs) were estimated. Fine and
Gray competing risk analysis was performed for the recur-
rence with death as a competing risk. The univariate asso-
ciations between dexamethasone usage and overall survival
were assessed using Kaplan-Meier survival analysis to-
gether with the log-rank test. We also conducted a sensitiv-
ity test to assess the robustness of our findings with
respect to the relationship between dexamethasone and
each of recurrence and mortality, wherein we performed
propensity score matching. Variables were adjusted to fac-
tors including BMI, hypertension, and diabetes mellitus,
and the score was calculated with logistic regression. A
greedy heuristic algorithm was used to identify the opti-
mally matched groups without drop-outs; this excluded
cases with differences exceeding twice the standard devi-
ation (SD) during matching similar propensity scores. As a
result, 1-to-5 matching was chosen because it carried the
strongest statistical power. All statistical analyses were
conducted with SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA) except for Kaplan-Meier curves, which were
constructed using the R package version 3.0.2 (http://www.
r-project.org).
Results
Subjects
We collected the data from 2729 patients who under-
went surgery following their diagnosis with breast cancer
during the study period. Among them, 63 patients who
underwent multiple surgeries, 21 with unclear anaes-
thetic methods, and 17 who received preoperative
steroid therapy were excluded. Ultimately, 2628 patients
were analysed in our study. The patients were followed
up to December 2015. The mean (SD) follow-up period
for our study population was 70.1 (23.1) months.
Patients’ demographic data
A comparison of the characteristics of patients who re-
ceived dexamethasone (N = 236) and those who did not
(N = 2392) is shown in Table 1. These two groups had
similar baseline demographic data. However, there were
significant differences with respect to anaesthetic agent,
induction agent, nitric oxide use, antiemetic use, surgical
procedure, and chemotherapy/radiotherapy administra-
tion between the two groups.
Risk factors for postoperative recurrence in breast cancer
surgery
Table 2 presents the factors that affected postoperative
breast cancer recurrence as revealed by competing risk
analyses. Multivariate analyses revealed that cancer
recurrence was not associated with perioperative dexa-
methasone administration (hazard ratio [HR], 1.442; 95%
confidence interval [CI], 0.969–2.145; P = 0.071). Table 3
details the propensity 1-to-5 matching analysis for our pri-
mary findings. This also showed no association between
dexamethasone and postoperative recurrence (HR, 1.389;
Table 2 Competing risk analyses of factors associated with cancer recurrence after surgery for breast cancer (Continued)
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Oestrogen receptor
No 1 (ref) 1 (ref)
Yes 0.576 0.443 0.748 < 0.001 0.886 0.597 1.315 0.549
Progesterone receptor
No 1 (ref) 1 (ref)
Yes 0.605 0.467 0.783 < 0.001 0.835 0.571 1.222 0.355
Chemotherapy
No 1 (ref) 1 (ref)
Yes 3.265 2.213 4.818 < 0.001 0.958 0.580 1.582 0.866
Radiotherapy
No 1 (ref)
Yes 1.211 0.917 1.597 0.177
CI confidence interval, HR hazard ratio, BMI body mass index, HTN hypertension, DM diabetes mellitus, TIVA total intravenous anaesthesia, N2O nitrous oxide, BCS
breast conserving surgery, TNM tumour-node-metastasis
aPremedication: Midazolam 0.03 mg kg−1 was administered
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Table 3 Factors associated with postoperative cancer recurrence in patients with breast cancer after propensity score matching
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Dexamethasone
No 1 (ref) 1 (ref)
Yes 1.251 0.822 1.903 0.295 1.389 0.904 2.132 0.133
Age 0.982 0.964 1.000 0.055
Age (years)
< 40 1 (ref) 1 (ref)
40–49 0.736 0.466 1.162 0.188 1.053 0.655 1.690 0.832
50–59 0.572 0.347 0.944 0.029 0.614 0.364 1.037 0.068
60–69 0.685 0.361 1.301 0.248 0.603 0.289 1.258 0.177
≥70 0.613 0.186 2.017 0.421 0.453 0.126 1.628 0.225
BMI 0.977 0.922 1.035 0.436
BMI (kg m−2)
< 18.4 1.349 0.542 3.358 0.520 1.477 0.585 3.730 0.409
18.4–22.9 1 (ref) 1 (ref)
23–24.9 1.159 0.765 1.757 0.485 1.321 0.866 2.015 0.196
25–29.9 0.919 0.597 1.417 0.703 1.032 0.667 1.597 0.888
≥30 0.326 0.045 2.353 0.266 0.345 0.047 2.524 0.295
HTN
No 1 (ref) 1 (ref)
Yes 1.109 0.718 1.713 0.642 1.270 0.761 2.118 0.360
DM
No 1 (ref) 1 (ref)
Yes 1.438 0.755 2.740 0.269 1.502 0.742 3.040 0.259
Anaesthetic agents
TIVA 1 (ref) 1 (ref)
Volatile 0.575 0.235 1.406 0.225 0.782 0.312 1.960 0.600
N2O
No 1 (ref)
Yes 1.515 0.919 2.497 0.103
Transfusion
No 1 (ref)
Yes 1.894 0.265 13.547 0.525
Premedicationa
No 1 (ref)
Yes 0.873 0.611 1.249 0.458
Surgical procedure
BCS 1 (ref) 1 (ref)
Mastectomy 2.119 1.458 3.078 < 0.001 1.659 1.121 2.457 0.012
TNM staging
1 1 (ref) 1 (ref)
2 2.454 1.503 4.006 < 0.001 2.160 1.223 3.814 0.008
3 8.215 5.121 13.177 < 0.001 7.780 4.303 14.064 < 0.001
Oestrogen receptor
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95% CI, 0.904–2.132; P = 0.133). Other anaesthetic factors
also were not correlated with the recurrence. The type of
surgical procedure and higher TNM staging (stage 2 and
3) were significantly associated with breast cancer recur-
rence. Figure 1a shows the recurrence-free survival prob-
abilities following breast cancer surgery according to
dexamethasone administration; this showed no significant
influence due to dexamethasone (P = 0.295).
Related-factors for postoperative mortality in breast
cancer surgery
Table 4 presents the factors that potentially influence post-
operative mortality in patients with breast cancer following
Cox regression. Multivariate analyses revealed no associ-
ation between perioperative dexamethasone administration
and mortality (HR, 1.389; 95% CI, 0.904–2.132; P = 0.133).
Instead, this was significantly associated with old age (≥70
Table 3 Factors associated with postoperative cancer recurrence in patients with breast cancer after propensity score matching
(Continued)
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
No 1 (ref) 1 (ref)
Yes 0.564 0.400 0.796 0.001 0.783 0.463 1.325 0.363
Progesterone receptor
No 1 (ref) 1 (ref)
Yes 0.572 0.407 0.803 0.001 0.818 0.491 1.363 0.441
Chemotherapy
No 1 (ref) 1 (ref)
Yes 1.870 1.293 2.706 0.001 0.669 0.350 1.279 0.224
Radiotherapy
No 1 (ref)
Yes 1.683 1.139 2.486 0.009
CI confidence interval, HR hazard ratio, BMI body mass index, HTN hypertension, DM diabetes mellitus, TIVA total intravenous anaesthesia, N2O nitrous oxide,
BCS breast conserving surgery, TNM tumour-node-metastasis
In 1 to 5 propensity matching process, the basic characteristics of 1224 subjects in the control group were considered to be different from the dexamethasone group and
excluded from the final matching analyses. Consequently, 234 patients who received dexamethasone and 1170 patients who did not receive dexamethasone were included
aPremedication: Midazolam 0.03 mg kg−1 was administered
Fig. 1 a Probability of recurrence-free survival following breast cancer surgery as a function of dexamethasone administration. b Probability of
postoperative overall survival in breast cancer patients as a function of dexamethasone administration
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Table 4 Univariate and multivariate Cox regression analyses of factors associated with mortality after surgery for breast cancer
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Dexamethasone
No 1 (ref) 1 (ref)
Yes 1.051 0.652 1.696 0.837 1.256 0.770 2.047 0.361
Age 1.028 1.013 1.042 < 0.001
Age (years)
< 40 1 (ref) 1 (ref)
40–49 0.586 0.369 0.931 0.024 0.772 0.480 1.240 0.285
50–59 0.852 0.539 1.346 0.493 0.922 0.575 1.479 0.736
60–69 1.175 0.716 1.929 0.523 1.151 0.654 2.027 0.625
≥70 2.713 1.534 4.798 < 0.001 2.427 1.220 4.830 0.012
BMI 0.993 0.947 1.041 0.758
BMI (kg m−2)
< 18.4 1.564 0.810 3.021 0.183 1.271 0.653 2.474 0.480
18.4–22.9 1 (ref) 1 (ref)
23–24.9 1.14 0.788 1.649 0.488 1.180 0.813 1.715 0.384
25–29.9 1.016 0.696 1.483 0.934 0.963 0.657 1.413 0.847
≥30 1.209 0.527 2.775 0.654 1.265 0.545 2.939 0.584
HTN
No 1 (ref) 1 (ref)
Yes 1.564 1.128 2.166 0.007 1.048 0.703 1.563 0.817
DM
No 1 (ref) 1 (ref)
Yes 1.810 1.148 2.852 0.0107 1.217 0.732 2.023 0.450
Anaesthetic agents
TIVA 1 (ref) 1 (ref)
Volatile 0.497 0.123 2.017 0.328 3.036 0.738 12.485 0.124
N2O
No 1 (ref)
Yes 1.388 0.892 2.158 0.146
Transfusion
No 1 (ref) 1 (ref)
Yes 7.527 2.792 20.296 < 0.001 5.551 1.980 15.559 0.001
Premedicationa
No 1 (ref)
Yes 0.817 0.602 1.108 0.193
Surgical procedure
BCS 1 (ref) 1 (ref)
Mastectomy 3.073 2.169 4.355 < 0.001 2.244 1.556 3.236 < 0.001
TNM staging
1
2 1.902 1.275 2.838 0.002 1.591 0.994 2.545 0.053
3 6.312 4.318 9.226 < 0.001 5.435 3.338 8.850 < 0.001
Oestrogen receptor
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years), transfusion, the type of surgical procedure, higher
TNM staging (stage 3), and progesterone receptor-positive
status. Table 5 details the association between dexametha-
sone and postoperative mortality as identified after the
propensity 1-to-5 matching. While there was no associ-
ation between dexamethasone and postoperative mortality
(HR, 1.506; 95% CI, 0.886–2.561; P = 0.130), the type of
surgical procedure, higher TNM stage (≥3), and progester-
one receptor were significantly associated with postopera-
tive mortality. Figure 1b shows the postoperative overall
survival probability in patients according to dexametha-
sone use; this showed that dexamethasone did not signifi-
cantly influence the overall survival (P = 0.442).
Sub-group analyses for association between
dexamethasone and subtypes of breast cancer
In the sub-group analyses to specify association between
dexamethasone and subtypes of breast cancer including
ER-dependency, PR-dependency or TNM staging, there
was no association between dexamethasone and the
recurrence or mortality in ER-dependent breast cancer.
Instead, dexamethasone was significantly associated with
the risk of mortality in PR-positive breast cancer (HR
2.637, 95% CI 1.106–6.288, p = 0.029). Moreover, dexa-
methasone showed a significant tendency to increase
risk of the recurrence in TNM stage 1of breast cancer
(HR 2.976, 95% CI 1.106–6.288, p = 0.002).
Discussion
Dexamethasone is an effective and widely used agent
that is administered perioperatively to improve the
quality of recovery after surgery. However, dexametha-
sone can also induce immunosuppression and may
cause tumour cells to escape from the immune system.
As a patient’s perioperative management is only han-
dled by the anaesthesiologist, the choice of anaesthetic
agent may critically affect post-surgical outcomes.
Hence, anaesthesiologists should consider the possibil-
ity of immunosuppression before administering dexa-
methasone. From this perspective, investigating the
effects of perioperative dexamethasone administration
on postoperative oncologic outcomes, in patients who
were already immunocompromised due to the peri-
operative environment, is very important. In our study,
we found that perioperative dexamethasone was not
associated with recurrence or mortality of patients
after breast cancer surgery.
Stress response following surgery is part of the sys-
temic reaction to an injury, and it encompasses a wide
range of immunological, endocrinological, and haem-
atological effects [12]. Importantly, the inevitable
immunosuppression during the perioperative period
can allow tumour cells to evade the immune system,
leading to recurrence in patients who are prone to un-
detectable micrometastases [13], even though surgical
resection of a tumour remains the optimal curative
treatment. Previous investigations suggest that peri-
operative impairment of the immune system increases
the risk of cancer recurrence in patients undergoing
oncologic surgery [14, 15]. Glucocorticoids are in-
volved in postoperative suppression of natural killer
cell activity [16]; their role in immunosuppression
includes the significant suppression of lymphokine
production and cell proliferation [4], impairment of
natural killer function [6], and rendering tumour cells
more resistant to apoptosis [7]. Glucocorticoids are
also known to induce proliferation in normal cells such
as erythroid progenitor cells and fibroblasts [17, 18];
Table 4 Univariate and multivariate Cox regression analyses of factors associated with mortality after surgery for breast cancer
(Continued)
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
No 1 (ref) 1 (ref)
Yes 0.398 0.297 0.533 < 0.001 0.758 0.488 1.177 0.217
Progesterone receptor
No 1 (ref) 1 (ref)
Yes 0.369 0.274 0.496 < 0.001 0.565 0.367 0.870 0.010
Chemotherapy
No 1 (ref) 1 (ref)
Yes 1.870 1.293 2.706 < 0.001 0.674 0.403 1.128 0.133
Radiotherapy
No 1 (ref)
Yes 0.922 0.682 1.246 0.597
CI confidence interval, HR hazard ratio, BMI body mass index, HTN hypertension, DM diabetes mellitus, TIVA total intravenous anaesthesia, N2O nitrous oxide, BCS
breast conserving surgery, TNM tumour-node-metastasis
aPremedication: Midazolam 0.03 mg kg−1 was administered
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Table 5 Factors associated with postoperative mortality in patients with breast cancer after propensity score matching
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Dexamethasone
No 1 (ref) 1 (ref)
Yes 1.223 0.733 2.041 0.442 1.506 0.886 2.561 0.130
Age 1.005 0.983 1.028 0.636
Age (years)
< 40 1 (ref) 1 (ref)
40–49 0.607 0.331 1.113 0.107 0.979 0.517 1.855 0.949
50–59 0.763 0.416 1.400 0.382 0.778 0.411 1.473 0.440
60–69 1.165 0.574 2.364 0.673 0.962 0.419 2.208 0.927
≥70 1.087 0.318 3.714 0.894 0.866 0.226 3.323 0.834
BMI 0.991 0.925 1.063 0.810
BMI (kg m−2)
< 18.4 0.852 0.542 3.358 0.520 0.759 0.179 3.216 0.709
18.4–22.9 1 (ref) 1 (ref)
23–24.9 1.449 0.765 1.757 0.485 1.647 0.994 2.730 0.053
25–29.9 1.012 0.597 1.417 0.703 1.008 0.584 1.740 0.976
≥30
HTN
No 1 (ref)
Yes 1.692 1.052 2.723 0.030
DM
No 1 (ref)
Yes 1.775 0.858 3.672 0.122
Anaesthetic agents
TIVA 1 (ref) 1 (ref)
Volatile 1.050 0.258 4.272 0.946 1.400 0.332 5.892 0.647
N2O
No 1 (ref)
Yes 1.523 0.840 2.763 0.166
Transfusion
No 1 (ref) 1 (ref)
Yes 6.113 1.503 24.857 0.011 3.063 0.6900 13.600 0.141
Premedicationa
No 1 (ref)
Yes 0.796 0.515 1.231 0.305
Surgical procedure
BCS 1 (ref) 1 (ref)
Mastectomy 2.699 1.652 4.408 < 0.001 2.289 1.367 3.833 0.002
TNM staging
1 1 (ref) 1 (ref)
2 2.403 1.293 4.466 0.006 1.553 0.774 3.117 0.216
3 8.587 4.770 15.458 < 0.001 5.509 2.732 11.106 < 0.001
Oestrogen receptor
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and previous studies have shown that low concentra-
tions of dexamethasone also can induce in vitro prolif-
eration of cancer cells such as those derived from
glioma [19], astrocytoma [20], and Kaposi’s sarcoma
[21]. Hence, even though dexamethasone-induced im-
munosuppression may be temporary, it can aggravate
tumour cell evasion of immune surveillance.
The issue of perioperative dexamethasone-induced im-
munosuppression influencing oncological outcomes has
recently been investigated by other groups. Yu and col-
leagues retrospectively studied 515 patients who under-
went rectal cancer surgery and found a higher rate of
cancer recurrence in patients who received dexametha-
sone [22]. Moreover, patients receiving a single dose of
dexamethasone before undergoing colon cancer surgery
were shown to have a potentially increased risk of dis-
tant recurrence [23]. On the other hand, a retrospective
study of 309 women who underwent endometrial cancer
surgery showed that dexamethasone that was adminis-
tered to prevent postoperative nausea and vomiting was
not associated with an increased risk of cancer recur-
rence or with altered progression-free or overall survival
compared to patients who did not receive dexametha-
sone [24]. Additionally, De Oliveira et al. [25] demon-
strated that perioperative dexamethasone had no effect
on recurrence in patients diagnosed with ovarian cancer,
although they did not report survival data. Another
study found that perioperative dexamethasone might
improve postoperative survival in human pancreatic
adenocarcinoma [26].
Our finding that perioperative dexamethasone appears
to have no significant effect on postoperative outcomes
including recurrence free and overall survival of patients
who underwent breast cancer surgery may be explained
as follows: Dexamethasone has been shown to reduce
the perioperative stress response [27, 28]; therefore, the
direct immunosuppression caused by dexamethasone
may be counteracted by its protective effect on the nor-
mal stress response to surgical stimuli. Dexamethasone
also has pro-apoptotic properties that may lengthen the
survival of patients with certain types of cancer [29, 30].
Glucocorticoids can destroy cancerous lymphoid cells,
and are thus essential for treating lymph node tissue
malignancies.
In contrast to these favourable characteristics of dexa-
methasone, glucocorticoids in general may also induce
the growth of malignant solid tumours and increase
their dissemination as a consequence of decreasing
inter-cell adhesiveness and enhancing tissue permeabil-
ity. In this regard, two recent reports were published on
the relationship between glucocorticoid use and breast
cancer risk. They described no evidence of glucocortic-
oid use influencing breast cancer recurrence in Danish
populations [31, 32]. However, these studies included
breast cancer patients regardless of whether they under-
went surgery, and also investigated various types of glu-
cocorticoids combined. To the best of our knowledge,
ours is the first study to investigate the impact of peri-
operative dexamethasone on postoperative recurrence
and mortality in patients with breast cancer, and to
determine whether single-dose dexamethasone is safe in
patients undergoing breast cancer surgery.
Based on our findings, chemotherapy was not signifi-
cantly associated with postoperative recurrence and
Table 5 Factors associated with postoperative mortality in patients with breast cancer after propensity score matching (Continued)
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
No 1 (ref) 1 (ref)
Yes 0.338 0.222 0.514 < 0.001 0.699 0.374 1.305 0.261
Progesterone receptor
No 1 (ref) 1 (ref)
Yes 0.280 0.180 0.435 < 0.001 0.428 0.228 0.803 0.008
Chemotherapy
No 1 (ref) 1 (ref)
Yes 4.667 2.156 10.103 < 0.001 1.381 0.549 3.474 0.493
Radiotherapy
No 1 (ref)
Yes 1.473 0.926 2.343 0.102
CI confidence interval, HR hazard ratio, BMI body mass index, HTN hypertension, DM diabetes mellitus, TIVA total intravenous anaesthesia, N2O nitrous oxide, BCS
breast conserving surgery, TNM tumour-node-metastasis
In 1 to 5 propensity matching process, the basic characteristics of 1224 subjects in the control group were considered to be different from the dexamethasone
group and excluded from the final matching analyses. Consequently, 234 patients who received dexamethasone and 1170 patients who did not receive
dexamethasone were included
aPremedication: Midazolam 0.03 mg kg−1 was administered
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mortality in the multivariate analyses, in contrast to uni-
variate analysis results. This may be because of
confounding effects associated with chemotherapy and
TNM staging, as chemotherapy is administered accord-
ing to the TNM stage in breast cancer patients. How-
ever, we could not avoid investigating chemotherapy and
TNM stage together in our multivariate analysis model,
as both were critical for determining the effect of dexa-
methasone on postoperative outcomes. Moreover, a
higher TNM stage remained a critical risk factor for
postoperative recurrence and mortality despite chemo-
therapy. Although the administration of dexamethasone
to subjects with chemotherapy may lead to worsened
prognoses in patients with breast cancer, it likely has
little impact on the perioperative immunity of patients
because surgery is usually scheduled 1 month after com-
pleting chemotherapy at our institution. Moreover, while
the antiemetic regimen is prescribed according to the
degree of nausea experienced by patients, dexametha-
sone is not a routinely administered agent. Furthermore,
a large cohort study of breast cancer patients [32]
showed no evidence of an association between preopera-
tive systemic, inhaled, or intestinal-acting glucocorti-
coids and breast cancer recurrence. As our study was
designed to investigate the effect of a single dose of
dexamethasone during anaesthesia on oncologic out-
comes, we did not include the data of dexamethasone
administered for neoadjuvant chemotherapy. Addition-
ally, we performed sub-group analyses to find out more
association between dexamethasone and subtypes of
breast cancer such as ER-dependency, PR-dependency,
or TNM staging. In this result, we found that dexa-
methasone is associated with the risk of mortality in
PR-dependent breast cancer and recurrence in TNM
stage 1 after breast cancer surgery. This detrimental
effect of dexamethasone in TNM stage 1 and
PR-dependent breast cancer requires further studies with
sufficient sample size.
The present study is limited by its retrospective na-
ture. Our patients were not randomised, and the clin-
ical protocol was not standardised; therefore, selection
bias and the effects of unmeasured confounding vari-
ables cannot be excluded. Moreover, the factors that
influenced care providers to administer or forgo peri-
operative dexamethasone are unknown, although such
decisions were unlikely to be associated with tumour
status. Even though single-dose perioperative dexa-
methasone administration has known to have no asso-
ciation with an increased risk of acute postoperative
complications including wound infection, the lack of
information regarding dexamethasone-related adverse
effects other than recurrence or mortality was consid-
ered a weak point of the study. There may be limited
strength to the conclusion because of the relatively
small population who received dexamethasone com-
pared with the large total sample size. Nevertheless,
the reliability of our data was buttressed by the retro-
spective design to some extent, because our homoge-
neous patients comprising 2628 women were managed
perioperatively in a similar manner at the same
hospital. Above all, our analyses may have the statis-
tical power by the sensitivity test of 1-to-5 propensity
score matching, which led to well-matched groups and
minimized the potential for significant confounding.
Although randomised clinical trials are required for
definitive conclusions, our results from
post-propensity score matching ought to add valuable
insight despite the study’s limitations.
Conclusions
In conclusion, our results suggest that a single dose of
perioperative dexamethasone does not increase the risk
of recurrence in patients after breast cancer surgery, and
it appears to be safe in this patient population.
Abbreviations
BMI: Body mass index; CI: Confidence interval; ER: Oestrogen receptor; HER: Human
epidermal growth factor receptor 2; HR: Hazard ratio; PR: Progesterone receptor;
SD: Standard deviation; TNM: Tumour-node-metastasis
Acknowledgements
Not applicable
Funding
This study was not supported by any external funding sources.
Availability of data and materials
The datasets used and/or analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
MHK collected and interpreted the patient data regarding the postoperative
recurrence- and mortality- related factors including dexamethasone of breast
cancer, and was a major contributor in writing the manuscript. DWK was a major
contributor in analysing patient data regarding the postoperative outcomes of
breast cancer, and interpreted the association between dexamethasone and
recurrence and mortality after breast cancer. SP designed this study and collected
the patient data regarding the surgical information of breast cancer. JHK collected
the patient data regarding the surgical information of breast cancer. KYL collected
the patient data regarding the anaesthetic information of breast cancer. JH
collected the patient data regarding the anaesthetic information of breast cancer.
YCY was a major contributor in designing this study regarding the association
between dexamethasone and postoperative outcomes of breast cancer, and
interpreted the patient data and wrote the manuscript. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
Our protocol was approved by the Institutional Review Board and Hospital
Research Ethics Committee of Severance Hospital, Yonsei University Health
System (4-2017-0677). The board waived the requirement for informed
consents because this study was retrospective.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Kim et al. BMC Cancer          (2019) 19:251 Page 12 of 13
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Anaesthesiology and Pain Medicine, Severance Hospital,
Anaesthesia and Pain Research Institute, Yonsei University College of
Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. 2Department
of Policy Research Affairs, National Health Insurance Service Ilsan Hospital,
Goyang, Gyeonggi-do, Korea. 3Division of Breast Surgery, Department of
Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro,
Seodaemun-gu, Seoul 120-752, Republic of Korea. 4Department of Surgery,
National Health Insurance service Ilsan hospital, Goyang, Gyeonggi-do, Korea.
Received: 15 May 2018 Accepted: 12 March 2019
References
1. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases:
balanced proliferation and apoptosis in the presence of angiogenesis
suppression. Nat Med. 1995;1(2):149–53.
2. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor
immunosurveillance and immunotherapy. Nat Immunol. 2001;2(4):293–9.
3. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against
postoperative immunosuppression: could they reduce recurrence rates in
oncological patients? Ann Surg Oncol. 2003;10(8):972–92.
4. Kunicka JE, Talle MA, Denhardt GH, Brown M, Prince LA, Goldstein G.
Immunosuppression by glucocorticoids: inhibition of production of multiple
lymphokines by in vivo administration of dexamethasone. Cell Immunol.
1993;149(1):39–49.
5. Bush KA, Krukowski K, Eddy JL, Janusek LW, Mathews HL. Glucocorticoid
receptor mediated suppression of natural killer cell activity: identification of
associated deacetylase and corepressor molecules. Cell Immunol. 2012;
275(1–2):80–9.
6. Holbrook NJ, Cox WI, Horner HC. Direct suppression of natural killer activity
in human peripheral blood leukocyte cultures by glucocorticoids and its
modulation by interferon. Cancer Res. 1983;43(9):4019–25.
7. Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J.
Dexamethasone enhances cell resistance to chemotherapy by increasing
adhesion to extracellular matrix in human ovarian cancer cells. Endocr Relat
Cancer. 2010;17(1):39–50.
8. De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, Kendall MC, McCarthy RJ.
Dexamethasone to prevent postoperative nausea and vomiting: an
updated meta-analysis of randomized controlled trials. Anesth Analg.
2013;116(1):58–74.
9. De Oliveira GS Jr, Ahmad S, Fitzgerald PC, Marcus RJ, Altman CS, Panjwani
AS, McCarthy RJ. Dose ranging study on the effect of preoperative
dexamethasone on postoperative quality of recovery and opioid
consumption after ambulatory gynaecological surgery. Br J Anaesth. 2011;
107(3):362–71.
10. Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J,
Ameijide A, Siesling S, Mangone L, Ardanaz E, et al. Predictions of survival
up to 10 years after diagnosis for European women with breast cancer in
2000-2002. Int J Cancer. 2013;132(10):2404–12.
11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S,
Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of
Clinical Oncology/College of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.
12. Desborough JP. The stress response to trauma and surgery. Br J Anaesth.
2000;85(1):109–17.
13. Sekandarzad MW, van Zundert AAJ, Lirk PB, Doornebal CW, Hollmann MW.
Perioperative anesthesia care and tumor progression. Anesth Analg. 2017;
124(5):1697–708.
14. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect
cancer recurrence or metastasis? Br J Anaesth. 2012;109(Suppl 1):i17–28.
15. Shakhar G, Abudarham N, Melamed R, Schwartz Y, Rosenne E, Ben-Eliyahu S.
Amelioration of operation-induced suppression of marginating pulmonary
NK activity using poly IC: a potential approach to reduce postoperative
metastasis. Ann Surg Oncol. 2007;14(2):841–52.
16. Shakhar G, Blumenfeld B. Glucocorticoid involvement in suppression of NK
activity following surgery in rats. J Neuroimmunol. 2003;138(1–2):83–91.
17. Li S, Mawal-Dewan M, Cristofalo VJ, Sell C. Enhanced proliferation of human
fibroblasts, in the presence of dexamethasone, is accompanied by changes
in p21Waf1/Cip1/Sdi1 and the insulin-like growth factor type 1 receptor.
J Cell Physiol. 1998;177(3):396–401.
18. Ganguli G, Back J, Sengupta S, Wasylyk B. The p53 tumour suppressor
inhibits glucocorticoid-induced proliferation of erythroid progenitors. EMBO
Rep. 2002;3(6):569–74.
19. Langeveld CH, van Waas MP, Stoof JC, Sutanto W, de Kloet ER, Wolbers JG,
Heimans JJ. Implication of glucocorticoid receptors in the stimulation of
human glioma cell proliferation by dexamethasone. J Neurosci Res. 1992;
31(3):524–31.
20. Freshney RI. Effects of glucocorticoids on glioma cells in culture. Minireview
on cancer research. Exp Cell Biol. 1984;52(5):286–92.
21. Guo WX, Antakly T. AIDS-related Kaposi's sarcoma: evidence for direct
stimulatory effect of glucocorticoid on cell proliferation. Am J Pathol. 1995;
146(3):727–34.
22. Yu HC, Luo YX, Peng H, Kang L, Huang MJ, Wang JP. Avoiding perioperative
dexamethasone may improve the outcome of patients with rectal cancer.
Eur J Surg Oncol. 2015;41(5):667–73.
23. Singh PP, Lemanu DP, Taylor MH, Hill AG. Association between preoperative
glucocorticoids and long-term survival and cancer recurrence after
colectomy: follow-up analysis of a previous randomized controlled trial. Br J
Anaesth. 2014;113(Suppl 1):i68–73.
24. Merk BA, Havrilesky LJ, Ehrisman JA, Broadwater G, Habib AS. Impact of
postoperative nausea and vomiting prophylaxis with dexamethasone on
the risk of recurrence of endometrial cancer. Curr Med Res Opin. 2016;
32(3):453–8.
25. De Oliveira GS Jr, McCarthy R, Turan A, Schink JC, Fitzgerald PC, Sessler DI.
Is dexamethasone associated with recurrence of ovarian cancer? Anesth
Analg. 2014;118(6):1213–8.
26. Call TR, Pace NL, Thorup DB, Maxfield D, Chortkoff B, Christensen J, Mulvihill
SJ. Factors associated with improved survival after resection of pancreatic
adenocarcinoma: a multivariable model. Anesthesiology. 2015;122(2):317–24.
27. Karaman K, Bostanci EB, Aksoy E, Ulas M, Yigit T, Erdemli MO, Ercin U,
Bilgihan A, Saydam G, Akoglu M. Effects of dexamethasone and
pheniramine hydrogen maleate on stress response in patients undergoing
elective laparoscopic cholecystectomy. Am J Surg. 2013;205(2):213–9.
28. Cardinale F, Mastrototaro MF, Cappiello A, Caffarelli C, Caimmi S, Barberi S,
Bernardini R. Immunological modifications induced from products used
during the perioperative period. Int J Immunopathol Pharmacol. 2011;24(3
Suppl):S13–20.
29. Liu S, Wang B, Li S, Zhou Y, An L, Wang Y, Lv H, Zhang G, Fang F, Liu Z,
et al. Immune cell populations decrease during craniotomy under general
anesthesia. Anesth Analg. 2011;113(3):572–7.
30. Khan S, Lopez-Dee Z, Kumar R, Ling J. Activation of NFkB is a novel
mechanism of pro-survival activity of glucocorticoids in breast cancer cells.
Cancer Lett. 2013;337(1):90–5.
31. Sorensen GV, Cronin-Fenton DP, Sorensen HT, Ulrichsen SP, Pedersen L,
Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish
population-based case-control study. Breast Cancer Res. 2012;14(1):R21.
32. Lietzen LW, Ahern T, Christiansen P, Jensen AB, Sorensen HT, Lash TL,
Cronin-Fenton DP. Glucocorticoid prescriptions and breast cancer
recurrence: a Danish nationwide prospective cohort study. Ann Oncol. 2014;
25(12):2419–25.
Kim et al. BMC Cancer          (2019) 19:251 Page 13 of 13
